Myovant Sciences Ltd. Common Shares (MYOV): Price and Financial Metrics
GET POWR RATINGS... FREE!
MYOV POWR Grades
- Quality is the dimension where MYOV ranks best; there it ranks ahead of 68.31% of US stocks.
- The strongest trend for MYOV is in Value, which has been heading up over the past 31 weeks.
- MYOV ranks lowest in Momentum; there it ranks in the 11th percentile.
MYOV Stock Summary
- Myovant Sciences Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.08% of US listed stocks.
- MYOV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 4.83% of US stocks.
- With a year-over-year growth in debt of 192.92%, Myovant Sciences Ltd's debt growth rate surpasses 94.8% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Myovant Sciences Ltd, a group of peers worth examining would be DOMO, BGMD, BXRX, TBPH, and NVCN.
- MYOV's SEC filings can be seen here. And to visit Myovant Sciences Ltd's official web site, go to myovant.com.
MYOV Valuation Summary
- MYOV's price/sales ratio is 32.2; this is 171.73% higher than that of the median Healthcare stock.
- Over the past 58 months, MYOV's price/sales ratio has gone NA NA.
- MYOV's price/earnings ratio has moved NA NA over the prior 58 months.
Below are key valuation metrics over time for MYOV.
MYOV Stock Price Chart Interactive Chart >
MYOV Price/Volume Stats
|Current price||$19.81||52-week high||$30.90|
|Prev. close||$19.10||52-week low||$13.42|
|Day high||$20.10||Avg. volume||861,393|
|50-day MA||$21.90||Dividend yield||N/A|
|200-day MA||$21.27||Market Cap||1.81B|
Myovant Sciences Ltd. Common Shares (MYOV) Company Bio
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company was founded in 2016 and is based in Hamilton, Bermuda.
MYOV Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Myovant Sciences Ltd. To summarize, we found that Myovant Sciences Ltd ranked in the 5th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Myovant Sciences Ltd, consider:
- The compound growth rate in the free cash flow of Myovant Sciences Ltd over the past 0.24 years is -0.53%; that's better than only 3.42% of cash flow producing equities in the Healthcare sector, where it is classified.
- Myovant Sciences Ltd's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
- Myovant Sciences Ltd's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -23.5. This coverage rate is greater than that of only 3.83% of stocks we're observing for the purpose of forecasting via discounted cash flows.
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
MYOV Latest News Stream
|Loading, please wait...|
MYOV Latest Social Stream
View Full MYOV Social Stream
Latest MYOV News From Around the Web
Below are the latest news stories about Myovant Sciences Ltd that investors may wish to consider to help them evaluate MYOV as an investment opportunity.
Infinity Pharmaceuticals, Grove leads healthcare gainers; Dyadic, EyeGate Pharmaceuticals among major losers
Gainers: Infinity Pharmaceuticals (INFI) +62%, Grove (GRVI) +26%, Shineco (TYHT) +24%, Tilray (TLRY) +22%, NeuroMetrix (NURO) +19%.Losers: Dyadic (DYAI) -14%, EyeGate Pharmaceuticals (EYEG) -13%, NanoViricides (NNVC) -13%, Myovant Sciences (MYOV) -9%, Vivos Therapeutics (VVOS) -8%....
Myovant Sciences (NYSE: MYOV) stock is losing ground after the company reported earnings for its fiscal first quarter, the three-month period ended June 30, 2021. Investors upset about net product sales that weren't very impressive led the stock 12.5% lower this morning. Sales of products containing Myovant's gonadotropin-releasing hormone (GnRH) receptor antagonist, Orgovyx (relugolix), weren't as impressive as investors were expecting.
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -219.05% and -32.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
First fiscal quarter 2021 total revenues of $41.1 million; net product revenue from U.S. sales of ORGOVYX® of $10.5 million and MYFEMBREE® of $1.1 millionMYFEMBREE approved by the U.S. FDA in May 2021 as the first and only once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids; FDA approval triggered a $100.0 million milestone payment from Pfizer received in July 2021RYEQO® approved by the European Commission in July 2021 for the treatment of wo
Late last week, and early this week, markets showed a negative reaction to the spread of the coronavirus Delta variant. That was unsurprising; after all, we have recent experience of just how bad the virus pandemic can get, and just how harsh the crackdown can be. But looking at the situation for JPMorgan, chief global markets strategist Marko Kolanovic believes we should take an even keel, that this situation is not as bad as it seems. “The Covid-19 delta variant should not lead to new lockdowns, and despite the rise in cases mortality has significantly declined.
MYOV Price Returns